Pharma Focus Europe

Charles River Teams Up with Pluristyx to Broaden Human Pluripotent Stem Cell Offerings

Wednesday, February 21, 2024

Charles River Laboratories International, Inc. (NYSE: CRL) has recently announced a partnership with Pluristyx Inc., a leading provider in the field of tools, technologies, and services for cell therapy development. This collaboration enables Charles River to access a wide range of stem cell lines, including high-quality embryonic stem (ES) cells and induced pluripotent stem cells (iPSCs), which are vital for research purposes in the development of new therapeutics.

Pluristyx offers innovative products and technologies aimed at accelerating the development of novel therapies while simultaneously reducing timelines and downstream costs. Through this collaboration, Charles River will distribute various iPSCs, both wild-type and genetically engineered, along with a comprehensive portfolio of ES cell lines, including those representing normal and disease states. All cell lines provided by Pluristyx adhere to ethical standards, with full donor consent obtained for pluripotent cell lines, and the ES cell lines being registered and approved by the U.S. National Institutes of Health (NIH), allowing for their use in NIH-funded research. Pluristyx’s iPSC panCELLa™ platform incorporates proprietary safety-switch technology, which enhances the development of safer cell therapies.

Under the terms of the agreement, Charles River will distribute a wide range of ES and iPS cell lines for research purposes. Additionally, it will exclusively offer specific pluripotent stem cell lines derived under Good Tissue Practice to support their potential use in clinical settings. This collaboration complements Charles River’s existing portfolio of human cellular materials.

ES and iPS cells are invaluable tools for researchers, providing access to specialized and differentiated cells essential for studying disease mechanisms and developing effective therapies. By expanding its portfolio to include these cell lines, Charles River reinforces its position as a leader in providing human-derived biomaterials for various research applications, including stem cell biology, disease modeling, drug discovery, and cell therapy development.

Moreover, Charles River is committed to identifying technologies and supporting initiatives that minimize reliance on in vivo research models, aligning with its 4Rs mission. This partnership with Pluristyx grants Charles River clients access to essential research tools for advancing in vitro translational cell-based assays for drug discovery.

Charles River and Pluristyx facilitates access to valuable research tools, ultimately contributing to the development of safe and effective therapies for patients worldwide.

 

Source: businesswire.com

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva